Population model successfully developed to characterize BI-1910 pharmacokinetics and pharmacodynamics across a broad range of ...

Linda Duska, MD, FASCO, MPH, discusses the importance of the KEYNOTE-A18 study reinforcing the new standard of care of pembrolizumab plus concurrent chemoradiotherapy in locally advanced cervical ...

Sacituzumab govitecan plus pembrolizumab improves outcomes vs chemotherapy plus pembrolizumab in patients with previously untreated, PD-L1+ TNBC.

New phase 3 data show that sacituzumab govitecan plus pembrolizumab delays cancer progression in PD-L1-positive metastatic ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...

The drug Trodelvy (drug name sacituzumab govitecan-hziy) is showing promise for first-line metastatic triple-negative breast ...

We know from the phase 2 TROPHY-U-01 trial that sacituzumab govitecan is an active drug, with an objective response rate of ...

A pre-surgical combination therapy including pembrolizumab plus dabrafenib and trametinib (DTP) significantly improved ...

In patients with an aggressive form of breast cancer, treatment with the antibody-drug conjugate sacituzumab govitecan plus ...

Gilead has already announced intentions to bring the data, which demonstrated a 35 percent reduction in risk of progression ...

CHICAGO – The postoperative addition of nivolumab (Opdivo) to chemoradiotherapy (CRT) extended disease-free survival (DFS) in ...